Formulation Development and Evaluation of Sublingual Tablets of Enalapril Maleate Using Co-processed Superdisintegrants
DOI:
https://doi.org/10.37591/(rrjops).v5i3.529Abstract
Enalapril Maleate is anti-hypertensive drug and its oral bioavailability is 40%. Sublingual tablets of Enalapril Maleate were prepared to improve its bioavailability, to avoid pre-systemic metabolism and hepatic first pass elimination. Tablets were prepared by wet granulation technique using two different superdisintegrants KYRON-T-314 and INDION-414 in the different ratio (1:1, 1:2 and 2:1) by co-processing and physical mixing. FTIR (Fourier transform infrared spectroscopy) and DSC (differential scanning calorimetry) spectroscopic studies indicated that there are no drug-excipient interactions. Tablets were evaluated for precompression as well as post-compression parameters, such as weight variation, thickness, hardness, friability, in vitro disintegration time, wetting time, in vitro dispersion time, water absorption ratio, drug content, in vitro drug release study and ex-vivo permeation study. The result showed that the formulation containing co-processed superdisintegrant in the ratio of 1:2 (CP2) showed faster disintegration, wetting, dispersion and maximum drug release. The disintegration time of optimized formulation (CP2) was up to 7 sec. The % in vitro drug release of Enalapril Maleate was 100.52% in 3 min. Ex vivo permeation of CP2 was found to be 92.26±0.96% in 6 min. Formulation CP2 was subjected to stability studies for 3 months at 40±5ºC/75±5%RH. Tablets didn’t reveal any appreciable changes. From the present work it reveals that the co-processed superdisintegrants formulation are superior to physical mixture formulation. Sublingual tablets of Enalapril Maleate gives faster drug release because of presence of superdisintegrants and may improve bioavailability of Enalapril Maleate.
Keywords: Enalapril Maleate, sublingual tablet, KYRON-T-314, INDION-414,
co-processed superdisintegrant
Downloads
Published
Issue
Section
License
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
- I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
- I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
- I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
- I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
4. ________________
| We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |
